Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2016 May 17;7(20):29824-34.
doi: 10.18632/oncotarget.8035.

shRNA-armed conditionally replicative adenoviruses: a promising approach for cancer therapy

Jie Zhang  1 , Meng Ding  1 , Kai Xu  1 , Lijun Mao  1   2 , Junian Zheng  1
Affiliations
Review

shRNA-armed conditionally replicative adenoviruses: a promising approach for cancer therapy

Jie Zhang et al. Oncotarget. .

Abstract

The small-interfering RNAs (siRNAs) have been employed to knockdown the expression of cancer-associated genes and shown some promise in cancer therapy. However, synthetic siRNA duplexes or plasmid mediated delivery of siRNAs have several problems, such as short half-life, low transfection efficiency and cytotoxicity associated with transfection. Conditionally replicating adenovirus (CRAds) as the delivery vector for short hairpin RNAs (shRNAs) could overcome these limitations and have shown augmented anti-tumor effects in experimental studies and preclinical trials. In this review, we summarize recent progress in the development of CRAds-shRNA for cancer treatment. Combination of CRAds-shRNA with chemotherapeutics, radiation, dendritic cells, monoclonal antibodies and small-molecule inhibitors will be necessary to eradicate cancer cells and cancer stem cells and achieve superior outcomes. The use of CRAd platform for efficient delivery of shRNAs and foreign genes will open a new avenue for cancer therapy.

Keywords: RNA interference; cancer; conditionally replicating adenoviruses; target therapy.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Figures

Figure 1
Figure 1. A schematic diagram of anti-tumor effects of CRAd-shRNA based therapy
After CRAds infect and replicate in tumor cells, shRNAs are expressed within the nucleus where they spontaneously form hairpin RNAs and are transported to the cytoplasm. Then shRNAs are cleaved by Dicer into active siRNAs. Binding of the siRNA to RISC results in the activation of this complex, and after subsequent duplex unwinding, RISC facilitates the binding of target homologous mRNAs. Perfect binding sequences result in the cleavage and silencing of target genes.
Figure 2
Figure 2. The schematic stucture of CRAd vector for shRNA
A. Wild type adenovirus. B. In recombinant adenovirus, E1B55KD gene was replaced by one shRNA sequence expression cassette. C. CRAd vector harboring double-cistronic shRNA expression construct. D. CRAd armed with shRNA and tumor specific promoter. E. CRAd armed with shRNA and exogenous therapeutic genes.
See this image and copyright information in PMC

References

    1. Haussecker D, Kay MA. RNA interference. Drugging RNAi. Science. 2015;347:1069–1070. - PMC - PubMed
    1. Behlke MA. Progress towards in vivo use of siRNAs. Mol Ther. 2006;13:644–670. - PMC - PubMed
    1. Parato KA, Senger D, Forsyth PAJ, Bell JC. Recent progress in the battle between oncolytic viruses and tumours. Nature Reviews Cancer. 2005;5:965–976. - PubMed
    1. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144:646–674. - PubMed
    1. Rajecki M, Kanerva A, Stenman UH, Tenhunen M, Kangasniemi L, Sarkioja M, Ala-Opas MY, Alfthan H, Sankila A, Rintala E, Desmond RA, Hakkarainen T, Hemminki A. Treatment of prostate cancer with Ad5/3Delta24hCG allows non-invasive detection of the magnitude and persistence of virus replication in vivo. Mol Cancer Ther. 2007;6:742–751. - PubMed

Substances